Wells Fargo raised the firm’s price target on Vertex Pharmaceuticals to $555 from $540 and keeps an Overweight rating on the shares. Updated VX-880 data presented at at ADA supports curative potential with a good safety profile, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX: